title: The Long-term Effect of Adrenal Arterial Embolization for Unilateral Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.
abstract: Primary aldosteronism (PA) is a major cause of secondary hypertension, divided into two subtypes: unilateral and bilateral. Unilateral PA (u-PA) is surgically-curable. Medical treatment with mineralocorticoid receptors antagonists is recommended as a second-line treatment when the patients are not candidate for surgical treatment. The present case was a 39-year-old woman with u-PA, who had refused surgery, had suffered from adverse effects of medical treatment. She was treated with transcatheter adrenal arterial embolization (TAAE). Her blood pressure had been well controlled without progression of cardiorenovascular damage for 12 years. TAAE can be the third treatment option for u-PA patients.
authors.affiliation: Division of Endocrinology and Hypertension, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, Japan.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kometani
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoneda
authors.forename: Masashi
authors.initials: M
authors.lastname: Demura
authors.forename: Shigehiro
authors.initials: S
authors.lastname: Karashima
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Mori
authors.forename: Masashi
authors.initials: M
authors.lastname: Oe
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Sawamura
authors.forename: Rika
authors.initials: R
authors.lastname: Okuda
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yamagishi
authors.forename: Yoshiyu
authors.initials: Y
authors.lastname: Takeda
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000451:Mineralocorticoid Receptor Antagonists